[Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
[Combination chemotherapy with 5-FU and CDDP or CDDP analog for head and neck cancer].
复制标题
5-FU与CDDP或CDDP类似物联合化疗治疗头颈癌[J].
DOI：
--
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
M. Kanke
中科院分区：
文献类型：
--
作者：
M. Fujii;Y. Ohno;Y. Tokumaru;Y. Imanishi;M. Kanke
CDDP与5-FU联合化疗是治疗头颈癌的有效方案之一。我们研究了两种CDDP给药方案在CDDP-5-FU联合化疗中的效果和不良反应的差异。对于 13 名患者，从第 1 天到第 5 天连续 5 天给予 CDDP，每日剂量为 16 mg/m2（方案 A）。 14 名患者在第 1 天服用 80 mg CDDP（方案 B）。从第 1 天到第 5 天，以 700 mg/m2/天的剂量连续滴注 120 小时，给予 5-FU。方案 A 的缓解率为 77%；方案 A 的缓解率为 77%。对于方案 B，该比例为 64%。不良反应的模式显示出差异。方案B对肾功能的毒性比方案A更大。但方案A对骨髓功能有毒性。急性期恶心和呕吐在方案B中出现得更频繁。不良反应模式的差异取决于CDDP给药的时间表，这对于安全地将该方案应用于头颈癌患者来说似乎很重要。 CDDP给药方案应根据患者的肾功能和骨髓功能而改变。为了评估 UFT 作为辅助化疗的功效，UFT 口服给药。上颌窦癌患者经过手术或放射治疗后一年以上。 15 名接受 UFT 辅助化疗的患者的生存率明显优于未接受辅助化疗的患者。我们还研究了 CBDCA 和 FT 对晚期头颈癌患者的辅助化疗。从第 1 天到第 14 天使用 UFT（600 mg/天），并在第 7 天使用 CBDCA 350 mg/m2，重复两次以上。该方案对鼻咽癌患者显示出低毒性和更好的生存率。需要对这种辅助化疗方案进行更多临床试验。
Combination chemotherapy with CDDP and 5-FU is one of the effective regimens for head and neck cancer. We studied the difference in the effects and adverse effects between two kinds of schedules of CDDP administration for CDDP-5-FU combination chemotherapy. For 13 patients, CDDP was administered on 5 consecutive days from day 1 to day 5 at a daily dose of 16 mg/m2 (Regimen A). For 14 patients CDDP was administered 80 mg on day 1 (Regimen B). 5-FU was administered 700 mg/m2/ day as a continuous drip infusion for 120 hours from day 1 to day 5. For regimen A, the response rate was 77%; for regimen B, it was 64%. The pattern of adverse effects showed a difference. Regimen B was more toxic for renal function than regimen A. But regimen A showed toxicity for bone marrow function. Acute phase nausea and vomit appeared more frequently in regimen B. The difference in the adverse effect pattern, which depends on the schedule of CDDP administration, seems important in order to apply this regimen for head and neck cancer patients safely. The schedule of CDDP administration should be changes depending on the renal and bone marrow function of patients. In order to evaluate the efficacy of UFT as adjuvant chemotherapy, UFT was administered p.o. to patients with maxillary sinus carcinoma for more than one year after definitive treatment with surgery or radiotherapy. Fifteen patients with UFT adjuvant chemotherapy showed significantly better survival rates than patients without adjuvant chemotherapy. We also studied adjuvant chemotherapy with CBDCA and FT for patients with advanced head and neck cancer. Administration with UFT (600 mg/day) from day 1 to day 14 with CBDCA 350 mg/m2 at day 7 was repeated more than twice. This regimen showed low toxicity and better survival for nasopharyngeal cancer patients. More clinical trials with this regimen for adjuvant chemotherapy are needed.